Search Browse Earnings

CURIS INC

Nasdaq:CRIS

Biological Products, (No Diagnostic Substances)·LEXINGTON, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CURIS INC — SlamSEC

Revenue

$10.0M

-1.4% YoY

FY 2024

Adj. EBITDA

-$47.6M

-475.4% margin

FY 2024

Net Income

-$47.4M

-473.0% margin

FY 2024

EPS (Diluted)

-$8.96

FY 2024

Stock Price

$0.99

-2.9%

2026-03-06

52W Range

$0.77 – $3.18

P/E Ratio

-0.1x

Market Cap

$12.9M

Cash

$26.7M

FY 2024

Total Debt

$35.5M

FY 2019

Net Debt

$8.8M

FY 2019

Enterprise Value

$21.7M

Debt / EBITDA

-0.2x

FY 2024

EV / EBITDA

-0.5x

Employees

—

CEO

Dentzer James E

CFO

Duvall Diantha